From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.

John Matsoukas, Vasso Apostolopoulos, Anthony Zulli, Graham Moore, Konstantinos Kelaidonis, Kalliopi Moschovou, Thomas Mavromoustakos

Molecules (Basel, Switzerland) 2021 Jan 25

filter terms:

The octapeptide hormone angiotensin II is one of the most studied peptides with the aim of designing and synthesizing non-peptide mimetics for oral administration. To achieve this, cyclizations at different positions within the peptide molecule has been a useful strategy to define the active conformation. These studies on angiotensin II led to the discovery of Sarmesin, a type II angiotensin II antagonist, and the breakthrough non-peptide mimetic Losartan, the first in a series of sartans marketed as a new generation of anti-hypertensive drugs in the 1990s. Angiotensin II receptor blockers (ARBS) and angiotensin I converting enzyme inhibitors (ACEI) were recently reported to protect hypertensive patients infected with SARS-CoV-2. The renin-angiotensin system (RAS) inhibitors reduce excess angiotensin II and increase antagonist heptapeptides alamandine and aspamandine which counterbalance angiotensin II and maintain homeostasis and vasodilation.

Citation

John Matsoukas, Vasso Apostolopoulos, Anthony Zulli, Graham Moore, Konstantinos Kelaidonis, Kalliopi Moschovou, Thomas Mavromoustakos. From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy. Molecules (Basel, Switzerland). 2021 Jan 25;26(3)